New combo therapy offered against refractory T-cell lymphoma – Korea Biomedical Review

() () URL()

Medical doctors wrestling with recurrent, non-reactive T-cell lymphoma, an intractable disease with no standard treatments, have recently got a green light.

A research team, led by Professor Yang Deok-hwan of the Department of Hematology at Chonnam National University Hwasun Hospital (CNUHH), said it has developed a new treatment method. For the first time in the world, they proved that the combined therapy of Copanlisib and Gemcitabine cell chemotherapeutic treatment showed high efficacy in treating the disease.

They conducted phase 1 and 2 clinical trials on 28 patients with P13K signal transduction inhibitor, Copanrai combining with Gemcitabine chemotherapy. The former inhibitor controls the P13K signal, and the latter suppresses the proliferation of malignant B cells, selectively blocking P13K subtypes.

Six other hospitals Seoul National University Hospital, Samsung Medical Center, Yonsei Severance Hospital, Chonbuk National University Hospital, Busan National University Hospital, and Kyungbuk National University Hospital also participated in the study.

Researchers found that 72 percent of patients showed favorable reactions to the treatment with minor adverse effects, and developed a new therapy that supplements old therapy using single P12K with the combined inhibitor treatment.

Recurring and non-reactive peripheral T-cell lymphoma is regarded as incurable cancer, which does not have a standardized treatment yet. In the past, salvage chemotherapy or hematopoietic stem cell transplants after high-dose chemotherapy were conducted to treat such disease after the first treatment failed; however, patients were non-reactive or lived for less than five months after the treatment.

The new method is receiving attention for using the next generation sequencing (NGS) approach to classify gene abnormalities or mutations in peripheral T-cell lymphoma in therapeutic and non-response groups.

We are conducting additional predictive systems for blood cancer patients using AI to research on developing prognosis prediction programs, Professor Yang said.

The study results will be published in the Annals of Oncology.

See more here:
New combo therapy offered against refractory T-cell lymphoma - Korea Biomedical Review

Related Post